HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	sacituzumab govitecan-hziy Sensitive: A1 - Approval FDA - 1 day (New A1) sacituzumab govitecan-hziy Sensitive : A1 FDA - 1d	sacituzumab govitecan-hziy Sensitive: A1 - Approval FDA - 1 day sacituzumab govitecan-hziy Sensitive : A1 FDA - 1 day - (New A1)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	palbociclib Sensitive: A1 - Approval BMC Cancer - 5 days (New C3) palbociclib Sensitive : A1 BMC Cancer - 5d	palbociclib Sensitive: A1 - Approval BMC Cancer - 5 days palbociclib Sensitive : A1 BMC Cancer - 5 days - (New C3)
ER positive + ESR1 mutation	HER2 Negative Breast Cancer	ER positive + ESR1 mutation	HER2 Negative Breast Cancer	elacestrant Sensitive: A1 - Approval FDA - 1 week (New A1) elacestrant Sensitive : A1 FDA - 1wk	elacestrant Sensitive: A1 - Approval FDA - 1 week elacestrant Sensitive : A1 FDA - 1 week - (New A1)
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	pembrolizumab Sensitive: A2 - Guideline NCCN - 1 week (New A2) pembrolizumab Sensitive : A2 NCCN - 1wk	pembrolizumab Sensitive: A2 - Guideline NCCN - 1 week pembrolizumab Sensitive : A2 NCCN - 1 week - (New A2)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	CDK6 inhibitor Sensitive: B - Late Trials Endokrynol Pol - 2 weeks (New C3) CDK6 inhibitor Sensitive : B Endokrynol Pol - 2wk	CDK6 inhibitor Sensitive: B - Late Trials Endokrynol Pol - 2 weeks CDK6 inhibitor Sensitive : B Endokrynol Pol - 2 weeks - (New C3)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	CDK4 inhibitor Sensitive: B - Late Trials Endokrynol Pol - 2 weeks (New C3) CDK4 inhibitor Sensitive : B Endokrynol Pol - 2wk	CDK4 inhibitor Sensitive: B - Late Trials Endokrynol Pol - 2 weeks CDK4 inhibitor Sensitive : B Endokrynol Pol - 2 weeks - (New C3)
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	CFI-402257 Sensitive: B - Late Trials Treadwell Therap Press Release - 3 weeks (New B) CFI-402257 Sensitive : B Treadwell Therap Press Release - 3wk	CFI-402257 Sensitive: B - Late Trials Treadwell Therap Press Release - 3 weeks CFI-402257 Sensitive : B Treadwell Therap Press Release - 3 weeks - (New B)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	ribociclib Sensitive: A1 - Approval ribociclib Sensitive : A1	ribociclib Sensitive: A1 - Approval ribociclib Sensitive : A1
PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	alpelisib Sensitive: A1 - Approval alpelisib Sensitive : A1	alpelisib Sensitive: A1 - Approval alpelisib Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	abemaciclib Sensitive: A1 - Approval abemaciclib Sensitive : A1	abemaciclib Sensitive: A1 - Approval abemaciclib Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	everolimus Sensitive: A1 - Approval everolimus Sensitive : A1	everolimus Sensitive: A1 - Approval everolimus Sensitive : A1
BRCA2 mutation	HER2 Negative Breast Cancer	BRCA2 mutation	HER2 Negative Breast Cancer	talazoparib Sensitive: A1 - Approval talazoparib Sensitive : A1	talazoparib Sensitive: A1 - Approval talazoparib Sensitive : A1
BRCA1 mutation	HER2 Negative Breast Cancer	BRCA1 mutation	HER2 Negative Breast Cancer	talazoparib Sensitive: A1 - Approval talazoparib Sensitive : A1	talazoparib Sensitive: A1 - Approval talazoparib Sensitive : A1
BRCA1 mutation	HER2 Negative Breast Cancer	BRCA1 mutation	HER2 Negative Breast Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
BRCA2 mutation	HER2 Negative Breast Cancer	BRCA2 mutation	HER2 Negative Breast Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	fulvestrant Sensitive: A1 - Approval fulvestrant Sensitive : A1	fulvestrant Sensitive: A1 - Approval fulvestrant Sensitive : A1
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	CaT Sensitive: A2 - Guideline CaT Sensitive : A2	CaT Sensitive: A2 - Guideline CaT Sensitive : A2
HR negative + BRCA1 mutation	HER2 Negative Breast Cancer	HR negative + BRCA1 mutation	HER2 Negative Breast Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	letrozole Sensitive: A2 - Guideline letrozole Sensitive : A2	letrozole Sensitive: A2 - Guideline letrozole Sensitive : A2
BRCA2 mutation	HER2 Negative Breast Cancer	BRCA2 mutation	HER2 Negative Breast Cancer	PARP inhibitor Sensitive: A2 - Guideline PARP inhibitor Sensitive : A2	PARP inhibitor Sensitive: A2 - Guideline PARP inhibitor Sensitive : A2
BRCA1 mutation	HER2 Negative Breast Cancer	BRCA1 mutation	HER2 Negative Breast Cancer	PARP inhibitor Sensitive: A2 - Guideline PARP inhibitor Sensitive : A2	PARP inhibitor Sensitive: A2 - Guideline PARP inhibitor Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	ribociclib Sensitive: A2 - Guideline ribociclib Sensitive : A2	ribociclib Sensitive: A2 - Guideline ribociclib Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	docetaxel Sensitive: A2 - Guideline docetaxel Sensitive : A2	docetaxel Sensitive: A2 - Guideline docetaxel Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	albumin-bound paclitaxel Sensitive: A2 - Guideline albumin-bound paclitaxel Sensitive : A2	albumin-bound paclitaxel Sensitive: A2 - Guideline albumin-bound paclitaxel Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	ixabepilone Sensitive: A2 - Guideline ixabepilone Sensitive : A2	ixabepilone Sensitive: A2 - Guideline ixabepilone Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	vinorelbine tartrate Sensitive: A2 - Guideline vinorelbine tartrate Sensitive : A2	vinorelbine tartrate Sensitive: A2 - Guideline vinorelbine tartrate Sensitive : A2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	toremifene Sensitive: A2 - Guideline toremifene Sensitive : A2	toremifene Sensitive: A2 - Guideline toremifene Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	letrozole Sensitive: A2 - Guideline letrozole Sensitive : A2	letrozole Sensitive: A2 - Guideline letrozole Sensitive : A2
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	anastrozole Sensitive: A2 - Guideline anastrozole Sensitive : A2	anastrozole Sensitive: A2 - Guideline anastrozole Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	docetaxel + capecitabine Sensitive: A2 - Guideline docetaxel + capecitabine Sensitive : A2	docetaxel + capecitabine Sensitive: A2 - Guideline docetaxel + capecitabine Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	carboplatin + albumin-bound paclitaxel Sensitive: A2 - Guideline carboplatin + albumin-bound paclitaxel Sensitive : A2	carboplatin + albumin-bound paclitaxel Sensitive: A2 - Guideline carboplatin + albumin-bound paclitaxel Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2
HR negative + BRCA2 mutation	HER2 Negative Breast Cancer	HR negative + BRCA2 mutation	HER2 Negative Breast Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2

HER2 Negative Breast Cancer

Associations(415)

Associations
(415)